Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-02-01
What Is MOTS-c? Benefits, Research & Safety
A mitochondrial-derived peptide that regulates metabolic homeostasis and exercise adaptations, representing a novel class of signalling molecules.
Also known as:
Mitochondrial ORF of the 12S rRNA Type-c
Mitochondrial-Derived Peptide
Educational Content Only: This page provides research-based information for educational purposes. MOTS-c is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.
Quick Facts
Category
Longevity & Anti-Ageing
Half-Life
Limited human pharmacokinetic data available
UK Status
Not licensed for human use. Research compound only.
EU Status
Not approved for therapeutic use.
Overview
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino acid peptide encoded within the mitochondrial genome. Discovered in 2015 by researchers at the University of Southern California led by Dr. Pinchas Cohen, MOTS-c represents a novel class of signalling molecules—mitochondrial-derived peptides (MDPs).
Unlike most peptides which are encoded by nuclear DNA, MOTS-c is encoded by the mitochondrial 12S rRNA gene. This discovery challenged the traditional view that mitochondria primarily function as cellular powerhouses and revealed their role as signalling organelles.
MOTS-c has been shown to regulate metabolic homeostasis, enhance insulin sensitivity, and promote the beneficial effects of exercise. Research suggests it acts as an exercise mimetic—producing some of the metabolic benefits of physical activity even without exercise.
The peptide's levels appear to decline with age, and exercise increases its expression and secretion. This has generated significant interest in MOTS-c as a potential therapeutic for age-related metabolic dysfunction, type 2 diabetes, and as an exercise enhancement strategy.
MOTS-c remains in early research stages and is not approved for therapeutic use.
Discovery & History
MOTS-c was discovered in 2015 by the laboratory of Dr. Pinchas Cohen at the University of Southern California (USC) Leonard Davis School of Gerontology. The discovery emerged from research into novel peptides encoded within the mitochondrial genome.
Prior to this discovery, it was believed that mitochondrial DNA primarily encoded components of the electron transport chain and mitochondrial ribosomes. The identification of MOTS-c and other mitochondrial-derived peptides revealed that mitochondria could produce signalling molecules that regulate whole-body metabolism.
The initial publication demonstrated that MOTS-c could prevent age-dependent and diet-induced obesity and insulin resistance in mice. The peptide appeared to work by promoting metabolic homeostasis and activating AMPK (AMP-activated protein kinase), a key metabolic sensor.
Subsequent research showed that MOTS-c is secreted into circulation in response to exercise, suggesting it may mediate some of exercise's beneficial metabolic effects. Studies also revealed that MOTS-c levels decline with age, potentially contributing to age-related metabolic dysfunction.
Research into MOTS-c and other mitochondrial-derived peptides continues, representing an exciting new area of metabolism and ageing research.
Mechanism of Action
MOTS-c exerts its metabolic effects through several mechanisms:
**AMPK Activation**
MOTS-c activates AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis. AMPK activation promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis while inhibiting energy-consuming processes.
**Nuclear Translocation**
Remarkably, MOTS-c can translocate to the nucleus in response to metabolic stress, where it may directly regulate gene expression. This represents an unusual signalling mechanism for a mitochondrial-derived peptide.
**Glucose Metabolism**
MOTS-c enhances glucose uptake and utilisation by skeletal muscle, improving overall glucose homeostasis. It appears to promote the metabolic adaptations typically associated with exercise training.
**Folate-Methionine Cycle Regulation**
The peptide influences one-carbon metabolism through effects on the folate-methionine cycle, which is important for various biosynthetic and regulatory processes.
**Exercise Mimetic Effects**
MOTS-c reproduces some of the metabolic benefits of exercise, including improved insulin sensitivity and altered substrate utilisation. Exercise increases MOTS-c secretion, suggesting the peptide may mediate some exercise benefits.
**Stress Response**
MOTS-c appears to enhance cellular stress resistance, potentially contributing to the health-promoting effects of exercise and metabolic adaptation.
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Improved insulin sensitivity in animal models
- 2Prevention of diet-induced obesity in mice
- 3Enhanced glucose metabolism and uptake
- 4Activation of AMPK and metabolic regulation
- 5Exercise mimetic effects on metabolism
- 6Potential role in healthy ageing
- 7Improved mitochondrial function
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Not established; animal studies use various weight-based doses |
| Frequency | Variable in research settings |
| Duration | Not established for human use |
| Notes | MOTS-c is in early research stages without established human protocols. Any information on dosing should be considered highly experimental. Human clinical trials are needed to determine appropriate use. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (in animal research)
- Intraperitoneal injection (animal models)
| Half-Life | Stability |
|---|---|
| Limited human pharmacokinetic data available | Peptide stability data from research settings |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Limited safety data in humans
- Animal studies suggest generally well-tolerated
Rare Risks & Concerns
- Unknown long-term effects
- Effects on cancer cells uncertain
- Metabolic effects in diabetics could require medication adjustment
Contraindications
- Diabetes (potential blood glucose effects)
- Pregnancy and breastfeeding
- Active malignancy (effects unknown)
- Children and adolescents
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. Research compound only.
🇪🇺 European Union
Not approved for therapeutic use.
MOTS-c is an early-stage research compound. Human clinical trials are in planning stages. Not available through legitimate medical channels.
Clinical Studies Summary
MOTS-c: A Mitochondrial-Derived Peptide Regulating Metabolic Homeostasis
Discovery paper demonstrating MOTS-c's role in metabolic regulation and prevention of obesity and insulin resistance in mice.
Cell Metab. 2015;21(3):443-54View on PubMed
The Mitochondrial-Derived Peptide MOTS-c is Regulated by Exercise
Research showing exercise-induced increase in MOTS-c and its role in exercise adaptations.
Am J Physiol Endocrinol Metab. 2016View on PubMed
Looking for MOTS-c?
Source research-grade MOTS-c from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Research Guides
Related Peptides
GHK-Cu
A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.
Learn moreEpitalon
A synthetic tetrapeptide based on epithalamin, researched for its potential effects on telomerase activation and biological ageing.
Learn moreHumanin
A mitochondrial-derived peptide with cytoprotective and anti-apoptotic properties, researched for neuroprotection, metabolic regulation, and ageing.
Learn more